Determination of human leukocyte interferon by a microfluorimetric immunologic method]

The possibility of quantitative determination of human leucocyte interferon using FITC-labeled antiinterferon antibodies was studied. A highly specific antiinterferon immunoglobulin was obtained as a result of longterm immunization of a donkey with human leucocyte interferon followed by fractionation and immuno-absorbtion of immune plasma. This immunoglobulin was labeled with FITC and used for human leucocyte interferon assay in direct and indirect reactions of fluorescence immunoinhibition. The titres of different human leucocyte interferon preparations in this immunoassay were comparable with the titres of the same preparations detected by interferon inhibition of viral cytopathic effect.     

Comparison of the antiviral action of different human interferons against DNA and RNA viruses

Abstract Five different interferon preparations were compared for their antiviral activity against Herpes simplex virus type 1 (HSV-1) and several RNA viruses. The interferons used were: interferon α from human buffy coats, interferon β from human fibroblasts, interferon γ from human lymphocytes after stimulation with phytohemagglutinin (PHA), lymphoblastoid interferon from Namalva cells IFN-α (Ly) and cloned α ₂ interferon produced by Escherichia coli containing the human gene for interferon α ₂. All preparations were able to protect monolayers of HeLa cells against HSV-1 infection when low multiplicities were used. The five IFN preparations were also tested against encephalomyocarditis (EMC) virus, poliovirus and vesicular stomatitis virus (VSV).     

Perspectives on interferon research and on its therapeutic use

After briefly reviewing recent advances in the knowledge of various molecular species of interferon, some prospects of the basic research in this field are discussed: 1) interferon as a physiological hormone endowed with antiviral and immunomodulatory functions and possibly interacting with the neuroendocrine system; 2) interferon as an inducible protein, a model which allows a refined molecular analysis using the probes made available by cloning; 3) the various mechanisms of interferon action at the biochemical level. In the last section, the past and future of interferon as a therapeutic agent are examined. For its therapeutic evaluation, interferon needs to be compared with the best chemotherapeutic agents now available against viruses and tumors. Large scale clinical trials require a large production of interferons. Hence, a dilemma will be encountered: either pursue trials with natural preparations which are always a mixture of several types and subclasses of interferons in no defined proportions; wait for availability of the interferons produced by genetic recombinants which are cloned species, and try these various species, each one alone and in combination, or even more use hybrid molecular species. The availability of accurate markers for the action of interferon in man will be of great usefulness to study its therapeutic action and furthermore to define its indications. Finally, the possibility is raised that some non toxic interferon inducers, such as Poly A, Poly U, could also be used as well as interferon itself.     

Possible causes of fever after interferon administration

Several factors can be responsible for the febrile response evoked by interferon (IF) administration in man. Since different cells and inducers are used for production of IF, the pyrogenic substance may not always be the same. Leucocyte IF (LeIF) may contain endogeneous pyrogen (EP), fibroblast IF (FIF) may contain heterogeneous proteins and/or EP, and lymphoblastoid IF (LyIF) may contain a factor released by the transformed lymphocyte able to induce, in vivo, the release of EP from leucocytes. Finally, IF may be intrinsically pyrogenic and, if this is the case, until homogeneous IF is used, it may potentiate the action of the pyrogenic contaminants.     

Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes

Studies have been performed on the in vitro immunologic effects of homogeneous recombinant human leukocyte interferon, IFLrA. Large granular lymphocytes, enriched for natural killer (NK) cell activity, were pretreated wtih IFLrA or natural interferon preparations and then tested for augmentation of NK activity and of antibody-dependent cell-mediated cytoxicity (ADCC). Monocytes were tested for cytolytic and cytostatic activity in 48–72 hr radioisotopic assays performed in the presence or absence of interferon. Treatment with IFLrA caused significant augmentation of NK, ADCC, and monocyte-mediated cytotoxic activities. Even 10 units of IFLrA induced augmentation of NK activity, and 100 units or more boosted monocyte-mediated activity. The effects in each of these assays were species-specific, with no detectable effects on the activity of mouse effector cells. These results indicate that homogeneous recombinant interferon has potent in vitro immunomodulating effects and thus provide a basis for carefully examining the in vivo effects of this protein on host defenses in forthcoming clinical trials with cancer patients.     

新药原料——低毒性、抗病毒、抗肿瘤失配双链核糖核酸的研究进展

新药原料--低毒性、抗病毒、抗肿瘤失配双链核糖核酸的研究进展聂实践胡冬琴赵红罗薇（北京市营养源研究所真菌工程实验室）前言近年来,全球性病毒性疾病在不断增加,但对抗病毒药物的研究却进展缓慢。直至今日由病毒引起的恶性疾病（如恶性肿瘤,ＡＩＤＳ病等）仍无法医治,这已成为当今严重的社会问题。据统计约６０％的流行性传染病都是由病毒感染引起的,细菌感染仅占１５％。而目前世界各国批准使用的合成抗病毒药物仅...     

Alveolar macrophage lipoxygenase products of arachidonic acid: isolation and recognition as the predominant constituents of the neutrophil chemotactic activity elaborated by alveolar macrophages

Human immune interferon preparations have anticellular activity on human cell lines (WISH and HEp-2). This anticellular activity copurified with the human immune interferon and appears to be a function of the immune interferon molecule. On the basis of a unit of antiviral activity, purified human immune interferon had about 20 and 100 times more anticellular activity than purified fibroblast or leukocyte interferon, respectively. The possible implications of this finding in the treatment of human neoplasia are discussed.     

Fluorescence-activated cell sorting of human T and B lymphocytes. II. Identification of the cell type responsible for interferon production and cell proliferation in response to mitogens

We have employed the fluorescence-activated cell sorter to separate pure viable preparations of human T and enriched B lymphocytes. Using such preparations, we have demonstrated that both human T and B cells can respond to PHA and PWM in vitro in the presence of macrophages with proliferation and the production of interferon, a mediator of cellular immunity. However, selective T cell interferon production and proliferative response can be assessed at 3 days in culture; B cell interferon production and proliferative response is delayed to 5 and 7 days. T cells or T cell products are ineffective in inducing or accelerating B cell interferon or proliferative response at 3 days. The use of 3-day T cell interferon production as a new technique for the assessment of T cell effector function and competence is suggested.     

Effect of interferon on the course of experimental E coli-induced pyelonephritis

The effect of the type I interferon on the development and process of experimental pyelonephritis caused by E. coli was studied on mice weighing 12 to 14 g. Interferon was administered intraperitoneally in a dose of 1000 units on days 3 and 7 of the disease. It was shown that the administration of the type I interferon to the mice with experimental pyelonephritis promoted rapid elimination of bacteria from the kidneys, prevented their penetration to the contralateral (intact) kidney, prevented marked macro- and microscopic damages in the kidneys, lowered the intensity of the inflammatory reaction, and increased the phagocytic activity of neutrophils and the number of the E-rosette-forming lymphocytes in the thymus. The data provided experimental grounding for clinical trials of interferon preparations in treatment of bacterial pyelonephritis.     

RNase activity in human interferon preparations.

The level of RNase activity in human interferon preparations was examined. Although sequential purification of interferon resulted in nearly a 300-fold increase in specific activity, RNase-specific activity remained more or less constant. The implications of this finding for the analyses of the mode of action of interferon are discussed.     

A monoclonal antibody with broad reactivity to human interferon-alpha subtypes useful for purification of leukocyte-derived interferon

A monoclonal antibody to human interferon-alpha, termed HT-1 antibody, with a broad reactivity to various subtypes of interferon-alpha was prepared. It bound and neutralized all of the four subtypes of E. coli-derived human recombinant interferon-alpha (alpha 1, alpha 2, alpha 4, and alpha 6) tested; it also neutralized human natural leukocyte interferon but only partially. Human interferon-beta and -gamma were not bound. The antibody conjugated to Sepharose beads retained over 90% of human leukocyte interferon induced by Sendai virus. The bound interferon was recovered by acid elution in good yields and in almost pure form (specific activity was about 2 X 10(8) international units/mg protein). The purified interferon showed, in SDS-polyacrylamide gel electrophoresis, an activity profile with major peaks in a mol. wt. range of 17,000-22,000, which completely agreed with the profile shown by polyclonal antibody-purified interferon. Such purified leukocyte interferon-alpha preparations containing most of the naturally occurring subtypes can be useful for clinical and other purposes.     

The detection of antibodies to recombinant interferon alfa-2a in human serum

Three different procedures have been used for detecting antibodies to Roferon-A (recombinant human interferon alfa-2a, rHuIFN alpha-2a) in the serum of patients who received this interferon as part of ongoing clinical trials: an antiviral neutralization bioassay (ANB), the standard method recommended by the World Health Organization (WHO), and the more recently developed radioimmunoassay (RIA) and enzymeimmunoassay (EIA). Although the three tests are based on different principles, the correlation among them was excellent. The assays show differences in sensitivities with the ANB being the least sensitive of the three. The EIA equals the RIA in sensitivity, reproducibility, accuracy and labor and provides the advantage of safety and convenience in the use of non-radioactive materials. Therefore, the EIA has been selected as the most suitable assay for initial screening of the sera of patients receiving Roferon-A for the presence of antibodies to this interferon. EIA positive sera are then tested in the ANB to determine whether or not neutralizing activities are present.     

Proportion of lymphocytes forming E, EA, and EAC rosettes following treatment with human interferon preparations in vitro

The proportion of lymphocytes forming E, EA, and EAC rosettes after treatment with human interferon preparations in vitro was measured. While interferon increased the percentage of lymphocytes forming E rosettes, the percentage of cells forming EA rosettes was diminished. The proportion of lymphocytes forming EAC rosettes was not altered to any major extent by interferon treatment. The same effects were observed when fibroblast interferon, purified to homogeneity with regard to molecular weight, was used.     

Immune-type interferon-induced transfer of viral resistance.

Mouse immune-type interferon (type II), a lymphokine, caused the transfer of viral resistance from mouse L cells to human WISH cells. The interferon was incapable of protecting WISH cells in the absence of L cells. The transfer of viral resistance occurred with interferon preparations of various specific activities, and was in proportion to the interferon concentration in the preparations. The transferred resistance had the characteristics of an interferon-induced antiviral state in that it was blocked by actinomycin D, effective against different types of viruses, and resulted from an action on the cell rather than on the virus. Mouse immune-type interferon was more efficient than virus-type (type I) at eliciting the transfer of protection. The transfer phenomenon may represent a mechanism for amplification of the interferon system as a host defense against viral infection. Further, it serves as a model for studying the mechanism of lymphokine-induced transfer of information between cells.     

Homogeneous interferon from E. coli depresses hepatic cytochrome P-450 and drug biotransformation

A highly purified homogeneous human interferon produced from cloned genes depressed the levels of hepatic cytochrome P-450 and related xenobiotic metabolism. Using another cloned human interferon and several impure preparations of human and mouse interferon, it appears that only interferons with antiviral activity in the mouse depress cytochrome P-450 in that species. This is the first direct evidence that interferon decreases hepatic drug biotransformation and likely explains the depression of drug elimination which occurs during viral infections or following the administration of interferon inducers.     

Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing

Human mesenchymal stromal cells (MSC) can suppress T-cell activation in vitro in an indoleamine 2,3-dioxygenase (IDO)-dependent manner. However, their clinical effects on immune ailments have been inconsistent, with a recent phase III study showing no benefit in acute graft-versus-host disease (GvHD). We here tested the hypothesis that the banked, cryopreserved MSC often used in clinical trials display biologic properties distinct from that of MSC in the log phase of growth typically examined in pre-clinical studies. In freshly thawed cryopreserved MSC derived from normal human volunteers, we observed that MSC up-regulate heat-shock proteins, are refractory to interferon (IFN)-γ-induced up-regulation of IDO, and are compromised in suppressing CD3/CD28-driven T cell proliferation. Immune suppressor activity, IFN-γ responsiveness and induction of IDO were fully restored following 24 h of MSC tissue culture post-thaw. These results highlight a possible cause for the inefficacy of MSC-based immunotherapy reported in clinical trials using cryopreserved MSC thawed immediately prior to infusion.     

Bactericidal effects of macrophages of mice treated with interferon]

The preparations of interferon or virus-inhibiting factor produced in L cell (L-IF) and mouse brain (MB-IF) enhanced the killing of Staphylococcus aureus (S.a.) by the mouse peritoneal macrophage. The L-IF, heat-inactivated at 80 degrees or 60 degrees for 30 min., and mock L-IF could not enhance the killing of S.a. The heterologous human and rabbit interferon preparations didn't enhance the bactericidal activity of macrophage. The L-IF didn't have any effect on the release of lysozyme from the macrophages.     

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C

A potent, long-lasting form of interferon alpha-2a mono-pegylated with a 40 kilodalton branched poly(ethylene glycol) was designed, synthesized, and characterized. Mono-pegylated interferon alpha-2a was comprised of four major positional isomers involving Lys31, Lys121, Lys131, and Lys134 of interferon. The in vitro anti-viral activity of pegylated interferon alpha-2a was found to be only 7% of the original activity. In contrast, the in vivo antitumor activity was severalfold enhanced compared to interferon alpha-2a. Pegylated interferon alpha-2a showed no immunogenicity in mice. After subcutaneous injection of pegylated interferon alpha-2a, a 70-fold increase in serum half-life and a 50-fold increase in mean plasma residence time concomitant with sustained serum concentrations were observed relative to interferon alpha-2a. These preclinical results suggest a significantly enhanced human pharmacological profile for pegylated interferon alpha-2a. Results of Phase II/III hepatitis C clinical trials in humans confirmed the superior efficacy of pegylated interferon alpha-2a compared to unmodified interferon alpha-2a.     

Toxicity of Blastomyces dermatitidis

Following injections of the insoluble portion of disrupted yeast cells ofBlastomyces dermatitidis animals exhibited a biphasic pyrogenic response, a decrease in total serum proteins, and there was no release of interferon.     

Experimental (preclinical) study of genetically engineered human interferon based on recombinant clones of E. coli 74 and Pseudomonas Sp VG-84

The results of the experimental (preclinical) study of interferon alpha2 from Pseudomonas sp VG-84 obtained from the All-Union Research Institute of Genetics and Selection of Industrial Microorganisms in comparison with the preparations of interferon alpha2 from E. coli 74 and natural human interferon (obtained from the Gamaleya Institute of Epidemiology and Microbiology) are presented. Interferon alpha2 from Pseudomonas, a highly purified preparation, has been shown to possess pronounced biological activity (antiviral and antiproliferative) in the culture of human cells. The medicinal form of the preparation has proved to be completely safe and areactive for animals, which makes it possible to recommend the preparation for testing on volunteers.